Managing refractory lupus nephritis (LN) remains a major hurdle for specialists in nephrology and rheumatology. A recent real-world study indicates that UC-MSCs for lupus nephritis provide a safe and effective therapeutic alternative. Researchers evaluated 120 patients with refractory disease who had failed standard treatments. Consequently, the results show significant improvements in renal parameters and steroid requirements.

Clinical Efficacy and Renal Response

The study reported cumulative renal response rates of 38.3% at 3 months and 56.7% at the one-year mark. Furthermore, researchers noted that the estimated glomerular filtration rate (eGFR) improved significantly. This was especially true for patients in CKD stages 2 and 3a. Additionally, the cumulative relapse rate remained low at only 8.8% after 12 months. Thus, cell therapy offers a potential pathway for reversing chronic renal decline.

Predicting Response to UC-MSCs for lupus nephritis

Baseline renal function acts as a powerful predictor for treatment success. Specifically, patients with a baseline eGFR ≥ 45 ml/min/1.73 m² achieved a substantially higher response rate of 66.3%. In contrast, those with more advanced renal impairment showed less prominent recovery. Therefore, early intervention is critical for optimal results when using UC-MSCs for lupus nephritis. Logistic regression confirmed that baseline eGFR is an independent predictor of success.

Safety and Infusion Events

The safety profile of umbilical cord-derived mesenchymal stromal cells remains very favorable. Investigators recorded only a 2.1% rate of hyperacute adverse events across 146 total infusions. Additionally, they reported no severe adverse events during the follow-up period. Most infections were manageable, occurring in approximately 10.9% of the patient cohort. These findings support the use of allogeneic cells as a viable option for refractory LN cases.

Frequently Asked Questions

Is UC-MSC therapy safe for patients with lupus nephritis?

Yes, the therapy shows a favorable safety profile. Real-world data indicates that hyperacute adverse events are rare (2.1%), and no severe treatment-related adverse events were reported in this large study.

What is the success rate of UC-MSCs for lupus nephritis?

In refractory cases, the cumulative renal response rate reaches approximately 56.7% at 12 months. Patients with better baseline kidney function tend to have even higher success rates.

Which patients are the best candidates for this treatment?

Patients with a baseline eGFR of ≥ 45 ml/min/1.73 m² and those in early CKD stages (2 or 3a) are the most likely to benefit from UC-MSC infusions.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Zheng Y et al. Allogeneic umbilical cord-derived mesenchymal stromal cells for treatment of refractory lupus nephritis: a real-world study. Stem Cell Res Ther. 2026 Apr 18. doi: 10.1186/s13287-026-05021-5. PMID: 42001190.

2. Fan Y et al. Mesenchymal stem cell therapy for lupus nephritis: a review of current clinical evidence. J Clin Med. 2022;11(20):6075.

3. Barbado J et al. Umbilical cord-derived mesenchymal stem cells for systemic lupus erythematosus. Stem Cells Int. 2018;2018:1927064.